Roche: new data for Ocrevus and Enspryng
(CercleFinance.com) - Roche announces that new data in multiple sclerosis and optical neuromyelitis spectrum disorder will be presented at the MSVirtual2020 congress, to be held from 11 to 13 September.
"New data further reinforce OCREVUS (ocrelizumab) as a highly effective treatment option offering a favourable and consistent benefit:risk profile, with high treatment persistence and adherence," the Swiss healthcare group said.
It adds that Phase III data has demonstrated reduced relapse severity with Enspryng (satralizumab), its recently FDA-approved subcutaneous treatment of adults with Optic Neuromyelitis Spectrum Disorder.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
"New data further reinforce OCREVUS (ocrelizumab) as a highly effective treatment option offering a favourable and consistent benefit:risk profile, with high treatment persistence and adherence," the Swiss healthcare group said.
It adds that Phase III data has demonstrated reduced relapse severity with Enspryng (satralizumab), its recently FDA-approved subcutaneous treatment of adults with Optic Neuromyelitis Spectrum Disorder.
Copyright (c) 2020 CercleFinance.com. All rights reserved.